Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤Á¾¾ç ȯÀÚÀÇ ¿ä Áß Vascular Endothelial Growth Factor ÃøÁ¤ÀÇ ÀÓ»óÀû ÀÇÀÇ Clinical Impact of Urinary Vascular Endothelial Growth Factor (VEGF) in Patients with Transitional Cell Carcinoma of the Bladder

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 6È£ p.573 ~ 579
ÃÖÁøÈ£, ±èÀ±È­,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖÁøÈ£ (  ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

±èÀ±È­ (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
ÀÎü °íÇü Á¾¾çÀÇ ¼ºÀå°ú ÀüÀÌÀÇ À¯¹ß¿¡ À־ ½Å»ý Ç÷°üÀº Àý´ëÀûÀ¸·Î ÇÊ¿äÇϱ⠶§¹®¿¡
'Á¾¾çÀÇ ¼ºÀåÀº ½Å»ýÇ÷°üÈ­(angiogenesls)¿¡ Á¿ìµÈ´Ù'´Â °³³äÀÌ Á¤¸³µÇ¾î ÀÖ´Ù. °íÇü Á¾¾çÀÇ
¼ºÀå Ãʱâ(prevascularphase)¿¡ Á¾¾çÀº ¾çÀûÀ¸·Î ¸Å¿ì ÀÛ°í ¼¼Æ÷ÀÇ ¼öµµ ¸Å¿ì ÀûÁö¸¸ ½Å»ý
Ç÷°üÈ­°¡ ÀÌ·ç¾îÁø ´ÙÀ½¿¡ Á¾¾çÀº ±Þ°ÝÇÑ ¼ºÀå°ú ÀüÀÌ°¡ ÀÌ·ç¾î Áú ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ½Å»ý
Ç÷°üÈ­°¡ ¹Ýµå½Ã ¾Ç¼º Á¾¾ç¿¡¼­¸¸ ¹ß°ßµÇ´Â °ÍÀº ¾Æ´Ï¸ç ºÎ½Å ¼±Á¾°ú °°Àº Ç÷°ü ºÐÆ÷°¡ dz
ºÎÇÑ ¾ç¼º Á¾¾ç¿¡¼­µµ ±Þ°ÝÇÑ ½Å»ý Ç÷°ü Çü¼ºÀÌ ³ªÅ¸³­´Ù. Á¾¾çÀÇ ¼ºÀåÀÌ ½Å»ý Ç÷°üÈ­¿¡ µû
¶ó Á¿ìµÈ´Ù´Â Áõ°Å°¡ ¿©·¯ ¿¬±¸ °á°ú¿¡¼­ ¹àÇôÁ³À¸¸ç ½Å»ý Ç÷°üÈ­°¡ Áõ°¡µÇ¾î ÀÖÀ» °æ ¿ì
À¯¹æ¾Ï, ÀڱðæºÎ¾Ï, ¹æ±¤¾Ï ȯÀڵ鿡¼­ ÁÁÁö ¾ÊÀº ¿¹Èĸ¦ °®´Â´Ù´Â º¸°í°¡ ÀÖ´Ù. ¿©·¯ ÀÓ»ó
ÀûÀÎ °á°ú¿¡¼­ º¸¸é ÀÌ·¯ÇÑ ½Å»ýÇ÷°üÀÇ Çü¼ºÀº ´Ù´Ü°èÀÇ °úÁ¤ÀÌ ÇÊ¿ä·Î ÇÏ´Â µ¥ Ç÷°ü³»ÇÇ
¼¼Æ÷ÀÇ Áõ½Ä »Ó ¾Æ´Ï¶ó ±³¿øÁúºÐÇØÈ¿¼Ò(collagenase)¿Í ´Ü¹éºÐÇØÈ¿¼Ò¿¡ ÀÇÇØ ¸ð¼¼Ç÷°ü ÁÖÀ§
ÀÇ ¼¼Æ÷ÀÇ ±âÁúÀÌ ³ì¾Æ ¹ö¸° ÈÄ Ç÷°ü³»ÇÇ ¼¼Æ÷°¡ À̵¿ÇÏ°í ºÐÈ­ÇÏ¿© ÇϳªÀÇ ±â´ÉÀûÀÎ ¸ð¼¼
Ç÷°ü¸¦ Çü¼ºÇÏ°Ô µÈ´Ù. Áö±Ý±îÁö ½Å»ý Ç÷°üÈ­¿¡ °ü¿©ÇÏ´Â ¿ä¼ÒµéÀÌ ´Ù¾çÇÏ°Ô º¸°íµÇ¾î ÀÖ´Ù.
´ëÇ¥ÀûÀÎ °ÍÀ» ¿­°ÅÇÏ¸é ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀåÀÎÀÚµé(fibroblast growth factor, basic FGF, acidic
FGFµî), epidermal growth factor(EGF), transforming growth factor(TGF), platelet derived
endothelial cell growth factor(PDGF), vascular endothelial growth factor(VEGF) ¹×
angiogenin, angiotensin ¥±µî ¸¹Àº ÀÎÀÚµéÀÌ º¸°íµÇ¾ú´Ù. ÀÌ Áß Ç÷°ü³»¸· ¼ºÀåÀÎÀÚ(VEGF)
´Â Ç÷°üÀÇ ³»¸·¿¡ ¼±ÅÃÀûÀ¸·Î ¼ºÀåÀ» ÃËÁøÇÏ´Â ÀÛ¿ëÀ» ÇÑ´Ù´Â ¸é¿¡¼­ ¸Å¿ì Èï¹Ì·Î¿î ¿ä¼ÒÀÏ
»Ó ¾Æ´Ï¶ó Á¤»ó »ý¸®ÇÐÀû °úÁ¤À̵çÁö Á¾¾ç¿¡¼­ Ç÷°üÇü¼º°ú °°Àº º´¸®ÇÐÀûÀÎ °úÁ¤À̵çÁö °£
¿¡ ½Å»ýÇ÷°ü¿¡ À־´Â ¸Å¿ì ÁßÃßÀû ÀÎ ¿ªÇÒÀ» ÇÏ´Â ¿ä¼ÒÀÌ´Ù. ºñ´¢±â Á¾¾çÇÐ ºÐ¾ß¿¡ ÀÖ¾î
¼­µµ Àü¸³¼±¾Ï ¹× Àü¸²¼± ºñ´ëÁõ, ½Å¼¼Æ÷¾Ï, ¹æ±¤ Á¾¾ç µî¿¡¼­ ±× ÀÇÀǸ¦ ã´Â ¿¬±¸ °á°ú°¡
ÀϺΠº¸°íµÈ ¹Ù ÀÖÀ¸³ª VEGF¸¦ ÃøÁ¤ÇÏ´Â ¹æ¹ý·Ð¿¡ À־´Â ´ëºÎºÐ ¸é¿ª¿°»ö¹ýÀ» »ç¿ëÇÏ
¿´´Ù´ø°¡ VEGFÀÇ ¿ªÇÒÀ» °£Á¢ÀûÀ¸·Î ¿¹ÃøÇÒ ¼ö ÀÖ´Â Ç÷°ü ºÐÆ÷¸¦ ¸é¿ª ¿°»ö¹ýÀ¸·Î ÃøÁ¤
ÇÏ´Â µîÀÇ Á¦ÇÑÀû ÀÎ ¹æ¹ýÀÌ º¸°íµÇ¾ú´Ù. º» ¿¬±¸¸¦ ÅëÇÏ¿© ÀúÀÚ´Â ¹æ±¤¾ÏȯÀÚÀÇ ¿ä Áß¿¡¼­
enzyme linked immunosorbent assay(ELISA)¸¦ ÅëÇÏ¿© ÃøÁ¤ÇÑ VEGFÀÇ ÀûÁ¤¼º ¿©ºÎ¿Í ´ë
»ó ȯÀÚµéÀÇ ÀÓ»óÀû »óȲ°ú ±×¿¡ µû¸¥ VEGF¿ÍÀÇ ¿¬°ü°ü°è¿¡ ´ëÇÏ¿© ¿¬±¸ÇÏ°íÀÚ ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : Vascular endothelial growth factor(VEGF) is an important protein implicated
in tumors associated with microvascular hyperpermeability and angiogenesis. Recently,
the importance of VEGF in urologic tumors including prostatic cancer has been
demonstrated by the immunohistochemical analysis of cancer specimens. However, little
is known about the significance of the urinary VEGF value in primary bladder cancer.
Materials and Methods : In this study, we have investigated the urinary VEGF
concentration by ELISA and the urine creatinine concentration In 24h urine collection
was used corset the value. A total of 37 transitional cell carcinomas of the bladder were
assessed; 8 controls(group 1), 8 superficial bladder tumors(group 11), 11 invasive bladder
tumors(group 111) and 8 superficial bladder tumors that had undergone complete
transurethral resection(group IV).
Results : 1 . No correlation was observed between urinary VEGF concentrations and
aging, but excretion of urine creatinine decreased according to age(r=-0.4782, p=0.0028),
particularly being prominent in females(r=-0.39, p=0.015). 2. Multiple comparison
analysis(Duncan's multiple range test) of differences in urinary VEGF expression among
4 groups(1-lV) showed more higher in group 11 than any other of the three remaining
groups(p<0.05) and statistical comparison 4 groups was significant(p=0.0035). We also
obtained the same results as above when using age-adjusted ANCOVA test. 3.
Correlations between urinary VEGF expressions and tumor size and grade were not
significant in group 11(p)0.05). 4. When dividing group 111 into visible and invisible
subgroups, no significant differences were observed within the subgroups(p>0.05).
Conclusions : The evaluation of urinary VEGF concentrations is easy to perform and
our results suggest that it may contribute to the predictive diagnostic study of the
progression and prognosis of primary bladder cancer.(Korean J Urol 1998; 39: 573¡­9)

Å°¿öµå

Vascular endothelial growth factor; Transitional cell carcinoma; B1adder;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS